Finance

Lists
Q3 2026 earnings • released • EPS beat +11.45% • Revenue beat +3.01%
See results
AMGN34:BVMF
Amgen Inc. BDR
R$94.72
+1.00%
(+0.94) 1D
ኖቬም 5, 10:01:00 ጥዋት ጂ ኤም ቲ-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN34...
Open
R$94.72
High
R$94.72
Low
R$94.72
Mkt. cap
258.68 ቢ
Avg. vol.
418.00
Volume
10.00
52-wk high
R$94.72
52-wk low
R$47.76
Shares outstanding
540.63 ሚ
No. of employees
32 ሺ
Open
R$94.72
High
R$94.72
Low
R$94.72
Mkt. cap
258.68 ቢ
Avg. vol.
418.00
Volume
10.00
52-wk high
R$94.72
52-wk low
R$47.76
Shares outstanding
540.63 ሚ
No. of employees
32 ሺ
News stories
From web sources and news partners
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc. BDR
CEORobert A. Bradway
Employees31.5 ሺ
Founded1980
Headquartersታውዘንድ ኦካስ, ካሊፎርኒያ, ዩናይትድ ስቴትስ
SectorBiotechnology
Industry-
Websiteamgen.com
Last report
3 ኖቬም 2026
Fiscal period
Q3 2026
US$6.45 / US$5.79
+11.45%beat
Revenue / Est. (USD)
10.36 ቢ / 10.06 ቢ
+3.01%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ሴፕቴ 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
9.56 ቢ
9.87 ቢ
8.62 ቢ
10.05 ቢ
Cost of goods sold
2.74 ቢ
2.68 ቢ
2.50 ቢ
2.75 ቢ
Cost of revenue
2.74 ቢ
2.68 ቢ
2.50 ቢ
2.75 ቢ
Research and development expenses
1.90 ቢ
2.14 ቢ
1.72 ቢ
1.87 ቢ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.72 ቢ
1.95 ቢ
1.60 ቢ
1.74 ቢ
Operating expense
3.55 ቢ
4.18 ቢ
3.21 ቢ
3.73 ቢ
Total operating expenses
6.29 ቢ
6.85 ቢ
5.70 ቢ
6.48 ቢ
Operating income
3.26 ቢ
3.01 ቢ
2.91 ቢ
3.57 ቢ
Other non operating income
181.00 ሚ
143.00 ሚ
192.00 ሚ
145.00 ሚ
EBT including unusual items
3.92 ቢ
1.51 ቢ
2.08 ቢ
2.77 ቢ
EBT excluding unusual items
2.72 ቢ
2.51 ቢ
2.37 ቢ
3.06 ቢ
Income tax expense
705.00 ሚ
181.00 ሚ
265.00 ሚ
393.00 ሚ
Effective tax rate
17.98%
11.96%
12.72%
14.20%
Other operating expenses
-71.00 ሚ
82.00 ሚ
-113.00 ሚ
116.00 ሚ
Net income
3.22 ቢ
1.33 ቢ
1.82 ቢ
2.38 ቢ
Net profit margin
33.65%
13.51%
21.11%
23.62%
Earnings per share
5.64
5.29
5.15
6.29
Interest and investment income
-
408.00 ሚ
-
-
Interest expense
-685.00 ሚ
-1.06 ቢ
-657.00 ሚ
-673.00 ሚ
Net interest expenses
-685.00 ሚ
-653.00 ሚ
-657.00 ሚ
-673.00 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
4.57 ቢ
4.02 ቢ
4.03 ቢ
4.69 ቢ
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች